Detailed Information on Publication Record

@article{48197,
   author = {Lenárt, Sára and Lenárt, Peter and Šmarda, Jan and Remšík, Ján and Souček, Karel and Beneš, Petr},
   article_location = {BASEL},
   article_number = {11},
   doi = {http://dx.doi.org/10.3390/cancers12113328},
   keywords = {Trop2; TACSTD2; cancer; proliferation; metastases; epithelial-to-mesenchymal transition; therapy},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Trop2: Jack of All Trades, Master of None},
   url = {https://doi.org/10.3390/cancers12113328},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 48197
AU  - Lenárt, Sára - Lenárt, Peter - Šmarda, Jan - Remšík, Ján - Souček, Karel - Beneš, Petr
PY  - 2020
TI  - Trop2: Jack of All Trades, Master of None
JF  - Cancers
VL  - 12
IS  - 11
SP  - 1-28
EP  - 1-28
PB  - MDPI
SN  - 2072-6694
KW  - Trop2
KW  - TACSTD2
KW  - cancer
KW  - proliferation
KW  - metastases
KW  - epithelial-to-mesenchymal transition
KW  - therapy
UR  - https://doi.org/10.3390/cancers12113328
N2  - Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.
ER  - 

LENÁRT, Sára, Peter LENÁRT, Jan ŠMARDA, Ján REMŠÍK, Karel SOUČEK and Petr BENEŠ. Trop2: Jack of All Trades, Master of None. \textit{Cancers}. BASEL: MDPI, 2020, vol.~12, No~11, p.~1-28. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers12113328.